Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory study evaluating the effects of a single administration of NYX-2925 versus placebo on synaptic plasticity, a biological measure of changes in neural cell communication

Trial Profile

An exploratory study evaluating the effects of a single administration of NYX-2925 versus placebo on synaptic plasticity, a biological measure of changes in neural cell communication

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs NYX 2925 (Primary)
  • Indications Fibromyalgia; Neurological disorders; Neuropathic pain
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Nov 2018 New trial record
    • 12 Nov 2018 According to an Aptinyx media release, the company plans to submit the detailed results of the study for publication and presentations at future scientific and medical meetings.
    • 12 Nov 2018 Results presented in an Aptinyx the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top